Relieved for metastatic adenocarcinoma with negative EGFR mutation

Mr. Usep was so depressed after being diagnosed with lung cancer 3–4 months ago. He had initially experienced shortness of breath due to fluid in his lungs since mid-2025 and had repeatedly consulted heart and lung specialists without improvement. Eventually, pathological examination of the lung fluid revealed malignancy: metastatic adenocarcinoma with negative EGFR mutation (wild type).

A CT scan later showed two primary masses measuring 6cm and 5 cm, along with multiple small metastases throughout nearly his entire left lung and in his spine. Clinically, it was already at an advanced stage. Survival rates for advanced-stage lung cancer are also low, averaging only 4–11 months. The chance of surviving more than five years is less than 5%. He had lost 8 kg in just one month but his wife continued supporting and accompany him in seeking alternative ways

Mr. Usep began using ECCT in mid-November 2025, together with chemotherapy. His progress was relatively rapid. After one month of use, he was able to stop using the wheelchair, although his spinal pain temporarily worsened due to nerve stimulation effects from cancer cells dying (rupturing) as a result of the therapy. A CT scan after two months showed significant improvement; the previously massive lung lesions were reduced to residual tissue that would likely turn into scar tissue.

After three months. His condition was dramatically different from his first visit, when he appeared helpless in a wheelchair. Hopefully he will continue to improve fully and remain healthy.